Wednesday, March 22, 2023
Spread the love
Home Business Balaxi Pharmaceuticals Growth Remains Robust on Back of Geographical Expansions

Balaxi Pharmaceuticals Growth Remains Robust on Back of Geographical Expansions

Spread the love

Hyderabad, Telangana, India

  • Revenue growth of 40.3% on YoY basis, with operating EBITDA of Rs. 15.29 crore
  • PAT stood at Rs. 8.23 crore
  • Revenue from Pharmaceutical business grew by 40.4% Y-o-Y

Balaxi Pharmaceuticals Limited (Balaxi), a branded IPR-based pharmaceutical company headquartered in Hyderabad, reported its results for the third quarter of financial year 2023 ended December 31, 2022.

Financial Highlights:

Particulars (INR Crore)

Q3FY23

Q3FY22

YoY

Revenue

86.58

61.72

40.3%

Operating EBITDA

15.29

13.55

12.8%

EBITDA Margin %

17.66%

21.95%

(429 bps)

Profit After Tax

8.23

12.17

(32.4%)

PAT Margin %

9.5%

        19.7%

Earnings Per Share (INR)

8.21

12.18

(32.6%)

NOTE: Financial Results for Q3 FY23 are not strictly comparable with Q3 FY22 due to the consolidation of Balaxi Healthcare LDA Angola, which became a wholly owned subsidiary of Balaxi Global DMCC with effect from 1st January 2022.

  • Revenue: Higher contribution from the pharmaceuticals business led to Y-o-Y growth of 40.3% in revenues for Q3 FY23 compared to corresponding quarter last year. The share of LATM markets increased to 40.4% of pharmaceutical revenues, highlighting our ability to quickly expand geographical presence. Key contributions to growth came from recently launched operations in markets like Honduras and El Salvador that are showing stronger demand for our products apart from substantial growth in Guatemala. Our pharma business in Angola continues to generate strong cash flows that are being re-invested for expanding into new markets.
  • Operating EBITDA: During the quarter, operating EBITDA stood at Rs. 15.3 crore, a growth of 12.8% Y-o-Y. This was on account of increasing contribution from LATM markets and expansion into newer geographies. Operating EBITDA margin has declined by over 400 bps to 17.7% in Q3 FY23 – however, going forward with contribution from the newly entered market rising, there should be a steady rise in our margins.
  • Profit After Tax: During the quarter, foreign exchange fluctuations had an impact of Rs. 4.56 Cr. Q3 FY23 Profit After Tax after considering exchange rate fluctuations stood at Rs. 8.2 crore. Earnings per Share (EPS) for the quarter is Rs. 8.21 compared to Rs. 12.18 in the corresponding quarter last year.

Commenting on the results, Mr. Ashish Maheshwari, Chairman and Managing Director said, “During the quarter, we have strategically focused on our newly launched geographies in the Latin American markets – Guatemala, Honduras and El Salvador. These LATM markets have contributed 40% of our pharmaceuticals revenues and we are confident of increasing this further as we penetrate these markets and increase volumes. Our mature presence in Angola has also contributed with another steady performance contributing 60% of the pharmaceuticals business.

As on 31 December, the number of registered products in our portfolio expanded to 766 across six countries in Africa and Latin America. Apart from this, we have another 650 products under registration or in pipeline for registration. With the increase in the number of product offerings, we expect to further increase our market share in the countries of our focus. We also plan to launch our operations in new countries in these regions.

Furthermore, during the month of December, we conducted Ground Breaking Ceremony for our proposed EU-GMP compliant facility, which will boost our margin profile going ahead. We have appointed a leading design and engineering execution consultant for project management. Going ahead, once the operation at our manufacturing facility commences we look forward to operating a well-integrated and efficient supply chain that will support our growth and value enhancement objectives.”

–NewsVoir

RELATED ARTICLES

LEAVE A REPLY

Please enter your comment!
Please enter your name here

- Advertisment -

Most Popular

Recent Comments